Jie Jessie Zhou (Jie Zhou)

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 3

Top Topics

Respiratory Syndrome Coronavirus

Advanced Cancer

Top Venues

Clinical pharmacology and therapeutics

Journal of clinical pharmacology

European journal of drug metabolism and pharmacokinetics

This page only lists publications with an associated author ORCID identifier.

Publications

Jie Jessie Zhou, Yan Xu, Yang Chen, Jie Shao, Yaming Su, Zhenhua Xu, Honghui Zhou, Christopher O'Brien
Model-based Investigation of Inadequate Efficacy of Tesnatilimab, an Anti- Natural Killer Group 2 Member D (NKG2D) Monoclonal Antibody, in Moderately to Severely Active Crohn's Disease. Journal of clinical pharmacology (2023)
Mingxiang Liao, Jie Jessie Zhou, Kenton Wride, Denise Lepley, Terri Cameron, Mark Sale, Jim J Xiao
Population Pharmacokinetic Modeling of Lucitanib in Patients with Advanced Cancer. European journal of drug metabolism and pharmacokinetics 47 (5) (2022)
Virginia D Schmith, Jie Jessie Zhou, Lauren R L Lohmer
The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19. Clinical pharmacology and therapeutics 108 (4) (2020)